Citations

Clear

258 citation(s) found for "Ge, Tian".

TMOD-18. THE PATIENT DERIVED XENOGRAFT NATIONAL RESOURCE: A COMPREHENSIVE COLLECTION OF HIGH-GRADE GLIOMA MODELS FOR PRE-CLINICAL AND TRANSLATIONAL STUDIES
Tian, Shulan , Peng, Sen, Carlson, Brett L. , Kitange, Gaspar J. , Evers, Lisa, Decker, Paul A. , Kosel, Matthew , Klee, Eric W. , James, C. David , Eckel‐Passow, Jeanette E. , Verhaak, Roel G.W. , Jenkins, Robert B. , Vaubel, Rachael A. , Remonde, Dioval , Schroeder, Mark A. , Kollmeyer, Thomas M. , Mladek, Ann C. , Daniel, J. , Decker, Paul A. , Berens, Michael E. , Califano, Andrea , Lachance, Daniel Honore , Sulman, Erik P. , Tran, Nhan L. , Giannini, Caterina , Parney, Ian F. , Sarkaria, Jann N.

Mayo Clinic

Neuro-Oncology | November 5, 2018 | Volume: 20 | Issue: suppl_6 | Pages: vi272-vi272

10.1093/neuonc/noy148.1130 Get It

Treatment Strategy of a Patient With a Brain Arteriovenous Malformation and Cranial Dural Fistula: 2-Dimensional Operative Video
Sattur, Mithun G. , Abi-Aad, Karl R., Tian, Fucheng, Welz, Matthew E., Anderies, Barrett J. , Anderies, Barrett, Bendok, Bernard R.

Mayo Clinic

Operative Neurosurgery | September 6, 2018 | Volume: 16 | Issue: 5 | Pages: 636-636

10.1093/ons/opy208 | PMID 30202995 Get It

Abstract We present the case of a 56-yr-old right-handed male, after informed consent was obtained, who presented with acute confusion and agitation, on the background of a remote history of an uncomplicated resection of a left parietal grade 2 glioma. Imaging revealed a large, acute right temporal intracerebral hemorrhage (ICH). Standard vascular workup for the cause of the ICH included catheter angiography. No direct cause of the hemorrhage was revealed; however, a high grade parasagittal dural arteriovenous fistula (DAVF) with cortical venous reflux was noted close to the prior craniotomy site. The venous reflux was towards the left hemisphere, but it was hypothesized that similar reflux on the right side may have been present and was not presently evident due to thrombosis. The DAVF was embolized by endovascular means, followed by evacuation of the hematoma. Follow-up angiogram 7 mo later revealed a high-flow, right superior temporal cortical arteriovenous malformation (AVM). The DAVF unfortunately had also progressed. Endovascular occlusion of both lesions was attempted but was not successful. Subsequently, microsurgical resection for both the vascular malformations was performed with careful pre- and intraoperative planning to obtain a successful clinical and angiographic result. In this video, we summarize diagnostic and therapeutic nuances that have broad implications for the workup of ICH and the strategic management of a unique scenario involving a brain AVM and high-grade cranial dural fistula in the same patient. Prior to each procedure, informed consent was obtained from the patient, which includes consent for publication.
Abstract 1221: Chronic lymphocytic leukemia risk variants are associated with alteration of epigenetic states in regulatory regions
Yan, Huihuang , Tian, Shulan , Kleinstern, Geffen , Slager, Susan L.

Mayo Clinic

Cancer Research | August 17, 2018 | Volume: 78 | Issue: 13_Supplement | Pages: 1221-1221

10.1158/1538-7445.am2018-1221 Get It

Abstract Chronic lymphocytic leukemia risk variants are associated with alteration of epigenetic state in regulatory regions The vast majority of disease-associated single-nucleotide polymorphisms (SNPs) identified by genome-wide association studies (GWASs) reside in noncoding genomic regions. Functional impact of noncoding casual variants on target gene expression often involves regulatory mechanisms, typically through altering local chromatin accessibility, histone modifications, transcription factor (TF) binding affinity and chromatin interactions. In chronic lymphocytic leukemia (CLL), we and others have identified 41 GWAS risk variants, whose mechanism of action in CLL etiology remains largely unknown. In this study, we aim to decipher the regulatory potential of these variants and to better understand the mechanisms contributing to dysregulation of genes implicated in CLL pathogenesis. We performed ChIP-seq for H3K4me3, H3K4me1, H3K27ac and H3K27me3 in CLL. In addition, we also analyzed over 250 public ChIP-seq, ATAC-seq, DNase-seq, FAIRE-seq, and chromatin interaction data in CLL, B cells and/or lymphoblastoid cell lines. Comparing the 41 index SNPs and the nearby SNPs they associated with in linkage disequilibrium (R2 at least 0.5 in the EUR ethnic group in 1000 Genomes Project) to the above epigenetic data sets revealed overlaps with regulatory regions in 38 of the risk loci, with 28 of the loci overlapping super-enhancers. We used two approaches to elucidate the mechanisms of potential SNP causality. First, we used GATK UnifiedGenotyper to infer genotype for the SNPs that overlapped open chromatin regions and ChIP-seq peaks, by which evidence of imbalance between reference and alternative allele was identified at heterozygous sites. Second, for SNPs located within open chromatin regions or ChIP-seq peaks, we used FIMO program to scan the 100bp sequences centered on the SNPs for significant matches (p=1e-05) to the position weight matrices in five TF binding motif databases; SNPs that had TF motifs altered by the alternative alleles were retained. Together, these two approaches revealed evidence for allele imbalance or TF binding motif alterations at 36 of the 38 CLL risk loci, suggesting the generality of epigenetic regulation in CLL pathogenesis. Further analysis of chromatin interaction, gene expression and expression quantitative trait loci data will likely link the casual SNPs to their target genes. Citation Format: Huihuang Yan, Shulan Tian, Geffen Kleinstern, Susan Slager. Chronic lymphocytic leukemia risk variants are associated with alteration of epigenetic states in regulatory regions [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 1221.
Addition of Vincristine and Irinotecan to Vincristine, Dactinomycin, and Cyclophosphamide Does Not Improve Outcome for Intermediate-Risk Rhabdomyosarcoma: A Report From the Children’s Oncology Group
Hawkins, Douglas S. , Chi, Yueh-Yun, Anderson, James R. , Tian, Jing , Arndt, Carola A.S., Bomgaars, Lisa , Donaldson, Sarah S. , Hayes‐Jordan, Andrea , Mascarenhas, Leo , McCarville, Mary Beth, McCune, Jeannine S. , McCowage, Geoffrey , Million, Lynn , Parham, David M. , Rodeberg, David A. , Rudzinski, Erin R. , Shnorhavorian, Margarett , Spunt, Sheri L. , Skapek, Stephen X. , Teot, Lisa A., Yock, Torunn I. , Meyer, William H. , McCowage, Geoff, Morris, Carol D. , Hawkins, Douglas S , Spunt, Sheri L , Donaldson, Sarah S , Mascarenhas, Leo , McCarville, Mary Beth, Wolden, Suzanne L.

Mayo Clinic

Journal of Clinical Oncology | August 9, 2018 | Volume: 36 | Issue: 27 | Pages: 2770-2777

10.1200/jco.2018.77.9694 | PMID 30091945 Get It

Purpose Intermediate-risk rhabdomyosarcoma (RMS) includes patients with either nonmetastatic, unresected embryonal RMS (ERMS) with an unfavorable primary site or nonmetastatic alveolar RMS (ARMS). The primary aim of this study was to improve the outcome of patients with intermediate-risk RMS by substituting vincristine and irinotecan (VI) for half of vincristine, dactinomycin, and cyclophosphamide (VAC) courses. All patients received a lower dose of cyclophosphamide and earlier radiation therapy than in previous trials. Patients and Methods Patients were randomly assigned at study entry to either VAC (cumulative cyclophosphamide dose, 16.8 g/m 2 ) or VAC/VI (cumulative cyclophosphamide dose, 8.4 g/m 2 ) for 42 weeks of therapy. Radiation therapy started at week 4, with individualized local control plans permitted for patients younger than 24 months. The primary study end point was event-free survival (EFS). The study design had an 80% power (5% one-sided α-level) to detect an improved long-term EFS from 65% (with VAC) to 76% (with VAC/VI). Results A total of 448 eligible patients were enrolled in the study. At a median follow-up of 4.8 years, the 4-year EFS was 63% with VAC and 59% with VAC/VI ( P = .51), and 4-year overall survival was 73% for VAC and 72% for VAC/VI ( P = .80). Within the ARMS and ERMS subgroups, no difference in outcome by treatment arm was found. Severe hematologic toxicity was less common with VAC/VI therapy. Conclusion The addition of VI to VAC did not improve EFS or OS for patients with intermediate-risk RMS. VAC/VI had less hematologic toxicity and a lower cumulative cyclophosphamide dose, making VAC/VI an alternative standard therapy for intermediate-risk RMS.
Efficacy of the MDM2 Inhibitor SAR405838 in Glioblastoma Is Limited by Poor Distribution Across the Blood–Brain Barrier
Calligaris, David, Feathers, Ryan W. , Vaubel, Rachael A. , Meaux, Isabelle, Mladek, Ann C. , Parrish, Karen E. , Barrière, Cédric, Debüssche, Laurent , Watters, James , Tian, Shulan , Decker, Paul A. , Eckel‐Passow, Jeanette E. , Kitange, Gaspar J. , Johnson, Aaron J. , Anastasiadis, Panos Z. , Agar, Nathalie Y.R. , Elmquist, William F. , Vaubel, Rachael A , Parney, Ian F , Agar, Nathalie Y R , Kim, Minjee , Daniel, J. , Zhang, Shuangling , Jin, Fang , Decker, Paul A. , Johnson, Aaron J. , Parney, Ian F. , Sarkaria, Jann N. , Mladek, Ann C

Mayo Clinic

Molecular Cancer Therapeutics | July 3, 2018 | Volume: 17 | Issue: 9 | Pages: 1893-1901

10.1158/1535-7163.mct-17-0600 | PMID 29970480 Get It

Abstract Controversy exists surrounding whether heterogeneous disruption of the blood–brain barrier (BBB), as seen in glioblastoma (GBM), leads to adequate drug delivery sufficient for efficacy in GBM. This question is especially important when using potent, targeted agents that have a poor penetration across an intact BBB. Efficacy of the murine double minute-2 (MDM2) inhibitor SAR405838 was tested in patient-derived xenograft (PDX) models of GBM. In vitro efficacy of SAR405838 was evaluated in PDX models with varying MDM2 expression and those with high (GBM108) and low (GBM102) expression were evaluated for flank and orthotopic efficacy. BBB permeability, evaluated using TexasRed-3 kDa dextran, was significantly increased in GBM108 through VEGFA overexpression. Drug delivery, MRI, and orthotopic survival were compared between BBB-intact (GBM108-vector) and BBB-disrupted (GBM108-VEGFA) models. MDM2-amplified PDX lines with high MDM2 expression were sensitive to SAR405838 in comparison with MDM2 control lines in both in vitro and heterotopic models. In contrast with profound efficacy observed in flank xenografts, SAR405838 was ineffective in orthotopic tumors. Although both GBM108-vector and GBM108-VEGFA readily imaged on MRI following gadolinium contrast administration, GBM108-VEGFA tumors had a significantly enhanced drug and gadolinium accumulation, as determined by MALDI-MSI. Enhanced drug delivery in GBM108-VEGFA translated into a marked improvement in orthotopic efficacy. This study clearly shows that limited drug distribution across a partially intact BBB may limit the efficacy of targeted agents in GBM. Brain penetration of targeted agents is a critical consideration in any precision medicine strategy for GBM. Mol Cancer Ther; 17(9); 1893–901. ©2018 AACR.
Risk factors for pleural effusion recurrence in patients with malignancy
Grosu, Horiana B. , Molina, Sofía, Casal, Roberto F. , Song, Juhee , Diaz‐Mendoza, Javier , Reddy, Chakravarthy, Yarmus, Lonny , Schiavo, Dante , Simoff, Michael , Johnstun, Jared, Raid, A.H. Zedan, Feller‐Kopman, David , Sahetya, Sarina K. , Foley, Finbar, Maldonado, Fabien , Noor, Laila , Miller, Russell , Mudambi, Lakshmi, Saettele, Timothy , Vial, Macarena R. , Eapen, Gerogie A., Ost, David E. , Garcia, Sofia Molina , Casal, Roberto , Yarmus, Lonny , Vial-Rodriguez, Macarena , Ost, David E , Li, Liang , Lee, Hans C. , Tian, Xin , Molina Garcia, Sofia

Mayo Clinic

Respirology | July 2, 2018 | Volume: 24 | Issue: 1 | Pages: 76-82

10.1111/resp.13362 | PMID 29966171 Get It

ABSTRACTBackground and objectiveThe main purpose of treatment in patients with malignant pleural effusion (MPE) is symptom palliation. Currently, patients undergo repeat thoracenteses prior to receiving a definitive procedure as clinicians are not aware of the risk factors associated with fluid recurrence. The primary objective of this study was to identify risk factors associated with recurrent symptomatic MPE.MethodsRetrospective multicentre cohort study of patients who underwent first thoracentesis was performed. The primary outcome was time to fluid recurrence requiring intervention in patients with evidence of metastatic disease. We used a cause‐specific hazard model to identify risk factors associated with fluid recurrence. We also developed a predictive model, utilizing Fine–Gray subdistribution hazard model, and externally validated the model.ResultsA total of 988 patients with diagnosed metastatic disease were included. Cumulative incidence of recurrence was high with 30% of patients recurring by day 15. On multivariate analysis, size of the effusion on chest X‐ray (up to the top of the cardiac silhouette (hazard ratio (HR): 1.84, 95% CI: 1.21–2.80, P = 0.004) and above the cardiac silhouette (HR: 2.22, 95% CI: 1.43–3.46, P = 0.0004)), larger amount of pleural fluid drained (HR: 1.06, 95% CI: 1.04–1.07, P < 0.0001) and higher pleural fluid LDH (HR: 1.008, 95% CI: 1.004–1.011, P < 0.0001) were associated with increased hazard of recurrence. Negative cytology (HR: 0.52, 95% CI: 0.43–0.64, P < 0.0001) was associated with decreased hazard of recurrence. The model had low prediction accuracy.ConclusionPleural effusion size, amount of pleural fluid drained, LDH and pleural fluid cytology were found to be risk factors for recurrence.
Characterizing Topological Patterns in Amnestic Mild Cognitive Impairment by Quantitative Water Diffusivity
Li, Ming , Schwarz, Christopher G. , Zhang, Jiange , Yin, Zhenyu , Qian, Lai, Zhao, Hui , Wang, Kun , Tian, Chuanshuai , Yu, Haiping , Chen, Weibo , Lu, Fangfei, Wu, Wenbo , Yang, Qing , Zhu, Bin , Schwarz, Christopher G , Zhang, Bing , Zhang, Xin , Zhang, Fang , Li, Ming, Xu, Yun

Mayo Clinic

Journal of Alzheimer's Disease | June 4, 2018 | Volume: 43 | Issue: 2 | Pages: 687-697

10.3233/jad-140882 | PMID 25114082 Get It

Whole‐exome sequencing for variant discovery in blepharospasm
Tian, Jun , Vemula, Satya R. , Xiao, Jianfeng , Defazio, Giovanni , Petrucci, Simona , Gigante, Angelo Fabio , Rudzińska, Monika , Kennelly, Kathleen D., Uitti, Ryan J. , Gerpen, Jay A. van, Hedera, Peter , Trimble, Elizabeth J. , LeDoux, Mark S. , Van Gerpen, Jay A, LeDoux, Mark S , Rudzinska-Bar, Monika , Valente, Enza Maria , Wszołek, Zbigniew K.

Mayo Clinic

Molecular Genetics & Genomic Medicine | May 17, 2018 | Volume: 6 | Issue: 4 | Pages: 601-626

10.1002/mgg3.411 | PMID 29770609 Get It

AbstractBackgroundBlepharospasm (BSP) is a type of focal dystonia characterized by involuntary orbicularis oculi spasms that are usually bilateral, synchronous, and symmetrical. Despite strong evidence for genetic contributions to BSP, progress in the field has been constrained by small cohorts, incomplete penetrance, and late age of onset. Although several genetic etiologies for dystonia have been identified through whole‐exome sequencing (WES), none of these are characteristically associated with BSP as a singular or predominant manifestation.MethodsWe performed WES on 31 subjects from 21 independent pedigrees with BSP. The strongest candidate sequence variants derived from in silico analyses were confirmed with bidirectional Sanger sequencing and subjected to cosegregation analysis.ResultsCosegregating deleterious variants (GRCH37/hg19) in CACNA1A (NM_001127222.1: c.7261_7262delinsGT, p.Pro2421Val), REEP4 (NM_025232.3: c.109C>T, p.Arg37Trp), TOR2A (NM_130459.3: c.568C>T, p.Arg190Cys), and ATP2A3 (NM_005173.3: c.1966C>T, p.Arg656Cys) were identified in four independent multigenerational pedigrees. Deleterious variants in HS1BP3 (NM_022460.3: c.94C>A, p.Gly32Cys) and GNA14 (NM_004297.3: c.989_990del, p.Thr330ArgfsTer67) were identified in a father and son with segmental cranio‐cervical dystonia first manifest as BSP. Deleterious variants in DNAH17, TRPV4, CAPN11, VPS13C, UNC13B, SPTBN4, MYOD1, and MRPL15 were found in two or more independent pedigrees. To our knowledge, none of these genes have previously been associated with isolated BSP, although other CACNA1A mutations have been associated with both positive and negative motor disorders including ataxia, episodic ataxia, hemiplegic migraine, and dystonia.ConclusionsOur WES datasets provide a platform for future studies of BSP genetics which will demand careful consideration of incomplete penetrance, pleiotropy, population stratification, and oligogenic inheritance patterns.
PD-1 Expression in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Large B-cell Richter Transformation (DLBCL-RT)
He, Rong , Viswanatha, David S., Chen, Dong , Dyke, Daniel Van, Tian, Shulan , Dao, Linda N. , Call, Timothy G. , Ansell, Stephen M. , Leis, José F., Mai, Ming, Hanson, Curtis A. , Chen, Dong , Ding, Wei , Shi, Min , Dyke, Daniel L. Van , Parikh, Sameer A. , Shanafelt, Tait D. , Rech, Karen L.

Mayo Clinic

American Journal of Surgical Pathology | May 15, 2018 | Volume: 42 | Issue: 7 | Pages: 843-854

10.1097/pas.0000000000001077 | PMID 29762141 Get It

Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) is a low-grade B-cell neoplasm and ∼2% to 9% patients develop an aggressive lymphoma, most commonly diffuse large B-cell lymphoma (Richter transformation, DLBCL-RT). Programmed death-1 (PD-1) pathway plays a crucial role in tumor host immunity evasion and its blockade has emerged as an effective anti-cancer immunotherapy. PD-L1 and PD-1 expression has shown predictive value in anti-PD cancer immunotherapy; however, it has not been well documented in CLL/SLL and DLBCL-RT. We evaluated PD-1 and PD-L1 expression by immunohistochemistry in 39 CLL/SLL, 15 DLBCL-RT, and 26 other DLBCL. In CLL/SLL, neoplastic B-cell PD-1 expression was weak and restricted to prolymphocytes/paraimmunoblasts within proliferation centers (PCs) and accentuated PCs of all sizes. Neoplastic B-cell PD-1 expression was highly prevalent and demonstrated increased intensity in DLBCL-RT, but in contrast was only rarely seen in other DLBCL (12/15 vs. 1/26; P<0.0001). An excellent correlation (90% concordance) was observed between neoplastic B-cell PD-1 immunohistochemistry positivity and molecularly defined CLL/SLL clonal relatedness in DLBCL-RT. PD-L1 expression was observed on the neoplastic B cells in rare DLBCL-RT and other DLBCL cases (1/15 vs. 1/26; P>0.05) as well as background histiocytes and dendritic cells. Overall survival of DLBCL-RT was significantly inferior to that of the other DLBCL (median, 16.9 vs. 106.1 mo; P=0.002). Our findings suggest a biological continuum from prolymphocytes/paraimmunoblasts in CLL/SLL PCs to the neoplastic B-cells in DLBCL-RT. The characteristic PD-1 expression in DLBCL-RT makes it a potential surrogate marker for determining clonal relatedness to CLL/SLL, which may have important prognostic and therapeutic implications.
The DEFUSE Trial: An Even Brighter DAWN for Patients With Acute Stroke and An Invigorated Role for Neurosurgeons in Acute Stroke Care
Tian, Fucheng, Abi-Aad, Karl R., Krishna, Chandan , Bendok, Bernard R.

Mayo Clinic

Neurosurgery | May 4, 2018 | Volume: 83 | Issue: 1 | Pages: E1-E2

10.1093/neuros/nyy168 | PMID 29917130 Get It